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The initiation of erythropoietin therapy for the purpose of renoprotection may need to be sooner than that for erythropoiesis, because erythropoietin may attenuate renal fibrosis through macrophage adjustment and endothelial cell protection by other uncertain mechanisms. Although, agents re-establishing the initial function of renal erythropoietin-producing cells could defer kidney fibrosis, however more studies should be carried out to determine the cellular target of erythropoietin in kidney and developinga new erythropoietin derivative for renal care.

Erythropoietin improves anemia in almost all patients with chronickidney disease (CKD) ([@R01],[@R02]). Anemia seems to be an indicator of tissue hypoxia which deteriorates kidney damage in CKD ([@R01]-[@R03]). Erythropoietin provokes red blood cell maturation in bone marrow and accentuates erythropoiesis ([@R03],[@R04]). It is a glycoprotein and a member of class I cytokines ([@R03],[@R04]). Peritubular interstitial fibroblasts in the renal cortex and outer medulla release most part of erythropoietin ([@R03]-[@R05]). The amount of oxygen supply to the tissues appears to control erythropoietin synthesis in a feedback pathway. Hypoxia induces a factor that regulates the renal erythropoietin gene transcription, which in turn, controls the productionof erythropoietin ([@R03]-[@R05]). Renal fibrosis is the final common event in all CKD types with different etiologies ([@R05],[@R06]). Persistent inflammation and transition of pericytes to myofibroblast causes kidney fibrosis and lesser amount of erythropoietin production ([@R04]-[@R07]). To date, administration of erythropoietin has had a significant impact on anemia improvement and reduced hypoxic tissue damage ([@R06]-[@R09]). New upcoming data suggest renoprotective potentials of erythropoietin. Recently, renoprotective effect of erythropoietin has become revealed which is not related to its erythropoetic properties ([@R10]-[@R12]). Different studies have shown renal protective effect of erythropoietin in acute kidney injury.

In a trial, we tested the hypothesis that erythropoietin protects renal tubular cells, enrolling 40 male rats. We showed that erythropoietin prevented the kidneys from acute kidney injury. Also, we found that administration of erythropoietin along with gentamicin reduces renal damage comparing control group. As well; erythropoietin was also effective, when it was administered after the occurrence of gentamicin-induced tubular damage. This revealed that erythropoietin was still effective after installation of renal damage ([@R13]). Therefore, erythropoietin seems to be a promising renal protective agent against nephrotoxic tubular damage caused by gentamicin or other aminoglycosides ([@R01]-[@R06],[@R14]). Recent studies have unveiled the cellular mechanism of renal erythropoietin synthesis and the following events leading to renal fibrosis ([@R02]-[@R07],[@R14]-[@R16]). Interestingly, fibroblasts from damaged tubular epithelial cells have no significant contribution in renal fibrosis, but renal erythropoietin-producing cells, originating from neural crests, differentiate into myofibroblasts in long time exposure to inflammation. It seems that they are involved in renal fibrosis ([@R06],[@R08],[@R17],[@R18]). Indeed, nearly all myofibroblasts that express α-smooth muscle act in originates from the renal erythropoietin-producingcells; they are normally peritubular interstitial fibroblastic cells expressing neural cell marker genes but they do not express α-smooth muscle actin. Macrophages and myofibroblasts are dominant cells causing kidney fibrosis. Macrophages can be differentiated to phenotype M1 (classically activated) or M2 (wound healing) regarding to the distinctive cytokine production ([@R01]-[@R08],[@R14]-[@R17]). While, erythropoietin can disconnect macrophages by abolishing the activity of NF-κB*, in vivo* macrophage regulation could be one of the mechanisms that explain the antifibrotic properties of erythropoietin in CKD ([@R13]-[@R18]). These important findings define the missing link in CKD between renal fibrosis and anemia ([@R14]-[@R18]). Some recent studies have indicated the improvement of renal function in CKD following administration of erythropoietin ([@R12]-[@R18]). Different notable evidences imply some benefits of erythropoietin other than the improvement of anemia such as the pleiotropic effects on the cardiovascular system and on the kidney ([@R11]-[@R17]). Clinical evidences suggest the erythropoietin renoprotective potential in patients with CKD, however more clinical trials are needed to clarify the time of initiation of erythropoietin treatment and the optimum dose of erythropoietin for reduction of disease progression in patients with CKD. The initiation of erythropoietin therapy for the purpose of renoprotection may need to be sooner than that for erythropoiesis, because erythropoietin may attenuate renal fibrosis through macrophage adjustment and endothelial cell protection by other uncertain mechanisms ([@R01]-[@R09]). Although, agents re-establishing the initial function of renal erythropoietin-producing cells could defer kidney fibrosis, more studies should be carried out to determine the cellular target of erythropoietin in kidney and developing a new erythropoietin derivative for renal care ([@R15]-[@R18]).
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